Not Signed In - INEGYT Is Superior To Simvastatin In Reducing Key Risk Markers Of Atherosclerosis - Confirmed
Mon, 11 Sep 2006 11:00 PM EST
... Results from new analyses of two clinical studies presented today at the 2006 World Cardiology Congress show that INEGY™ (ezetimibe/simvastatin) is effective for reducing apolipoprotein-B containing lipoproteins (apo-B) and C-reactive protein (CRP), both recognized risk markers for atherosclerosis. [click link for full article] ...
Related Topics
- Atherosclerosis
- Vitamin E Cream, Ointment, Gel
- Risk Factors
- Simvastatin
- Security Risk Assessment
- Cardiac Risk
- High Risk Pregnancy
- Superior Vena Cava Syndrome
- Arteriosclerosis/Atherosclerosis
- Bone Markers
- Youth Risk Behaviors
- Stroke secondary to atherosclerosis
- Morbidity & Mortality Weekly Report
- ALT
- CVD
- Youth Risk Behavior Surveillance System
- Tumor Markers
- Fluvastatin
- Increased risk of infection
- Increased risk for tuberculosis
email this page
print this page
bookmark this page
feedback on this page
